Please login to the form below

Not currently logged in
Email:
Password:

BioAlliance announces managerial changes

Dr Gilles Avenard resigns as board member and deputy CEO in charge of R&D, while Dr Pierre Attali becomes CEO

BioAlliance Pharma, a company dedicated to the supportive care and treatment of cancer patients, has announced changes to its management structure.

Dr Gilles Avenard has resigned as board member and deputy CEO in charge of R&D, while Dr Pierre Attali, who has been serving BioAlliance Pharma as chief medical officer for several years, has been appointed as the company's CEO.

Dominique Costantini, CEO of BioAlliance Pharma commented: "I am delighted by Pierre Attali's appointment. His international experience in drug development, notably at Synthelabo, and his hospital practice are major assets for both the company and its commercial partners when preparing the next launches of BioAlliance's products."

4th August 2010

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

digital launch
How can virtual pharma companies de-risk new product launches?
The risks and challenges involved in taking specialty drugs, biopharmaceuticals and drug/device combinations to market...
Not waving but drowning. Reflections on data curation in the age of information overload
...
digital healthcare chronic disease
Digital healthcare may revolutionise management of chronic diseases, but who is going to pay for it?
Providers are looking at digital solutions to transform this area of healthcare...

Infographics